Levothyroxine Sodium
- Product NDC
- 82804-314
- Requested package NDC
- 82804-314-30
- 11-digit product format
- 828040314
- Labeler code
- 82804
- Product ID
- 82804-314_d8bdea29-fc63-49b4-bc35-9029ec7b1bb9
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Levothyroxine Sodium
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Proficient Rx LP
- Application
- ANDA209713
- Marketing category
- ANDA
- Marketing start
- 2019-05-02
- Substance
- LEVOTHYROXINE SODIUM
- Active strength
- .05 mg/1
- Pharmacologic classes
- Thyroxine [CS], l-Thyroxine [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A209713-001 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-002 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-003 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-004 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-005 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-006 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-007 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-008 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-009 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-010 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-011 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-012 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A209713-001 | AB1 |
| A209713-001 | AB2 |
| A209713-001 | AB3 |
| A209713-002 | AB1 |
| A209713-002 | AB2 |
| A209713-002 | AB3 |
| A209713-003 | AB1 |
| A209713-003 | AB2 |
| A209713-003 | AB3 |
| A209713-004 | AB1 |
| A209713-004 | AB2 |
| A209713-004 | AB3 |
| A209713-005 | AB1 |
| A209713-005 | AB2 |
| A209713-005 | AB3 |
| A209713-006 | AB1 |
| A209713-006 | AB2 |
| A209713-006 | AB3 |
| A209713-007 | AB1 |
| A209713-007 | AB2 |
| A209713-007 | AB3 |
| A209713-008 | AB1 |
| A209713-008 | AB2 |
| A209713-008 | AB3 |
| A209713-009 | AB1 |
| A209713-009 | AB2 |
| A209713-009 | AB3 |
| A209713-010 | AB1 |
| A209713-010 | AB2 |
| A209713-010 | AB3 |
| A209713-011 | AB1 |
| A209713-011 | AB2 |
| A209713-011 | AB3 |
| A209713-012 | AB1 |
| A209713-012 | AB2 |
| A209713-012 | AB3 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A209713-001 | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A209713-002 | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A209713-003 | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A209713-004 | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A209713-005 | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A209713-006 | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A209713-007 | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A209713-008 | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A209713-009 | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A209713-010 | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A209713-011 | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A209713-012 | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-001 | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-002 | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-003 | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-004 | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-005 | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-006 | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-007 | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-008 | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-009 | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-010 | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-011 | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-012 | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-001 | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-002 | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-003 | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-004 | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-005 | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-006 | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-007 | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-008 | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-009 | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-010 | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-011 | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-012 | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-001 | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-002 | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-003 | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-004 | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A209713-001 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-001 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-001 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-002 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-002 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-002 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-003 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-003 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-003 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-004 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-004 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-004 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-005 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-005 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-005 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-006 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-006 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-006 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-007 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-007 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-007 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-008 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-008 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-008 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-009 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-009 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-009 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-010 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-010 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-010 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-011 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-011 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-011 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-012 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-012 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A209713-012 | AB3 | 3 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-001 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-001 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-001 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-002 | AB1 | 1 | c2088c7a36db… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Levothyroxine Sodium
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| LEVOTHYROXINE SODIUM | .05 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 9J765S329G | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 966221 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| d8bdea29-fc63-49b4-bc35-9029ec7b1bb9 | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals, Inc. | 2646a481-09a5-af6a-e063-6394a90a16da | 2024-11-06 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 924bb6e9-4b2b-406f-a0a8-376b1f22f1f5 | 2024-10-14 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCarePharmaceuticals, Inc. | 2380859a-5b65-f88f-e063-6394a90aa4e2 | 2024-10-02 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | DIRECT RX | a5f15022-1166-09fe-e053-2a95a90aa218 | 2024-05-23 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 804d64c9-9804-4d6d-adb2-5036c0be8b5c | 2023-12-12 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 82804-314-30 | 82804031430 | 30 TABLET in 1 BOTTLE (82804-314-30) | 30 tablet | 2026-09-11 | No | No | Current |